FDA Approved a Nasal Spray that Can Cure Drug-Resistant Depression
Medicine these days is quickly passing new milestones. It seems like the mankind is at the finish line of producing global medicine to cure HIV virus and AIDS. However, today we will talk to you about another disease, not as obvious at first sight, but just as dangerous and deadly. People have tried to cure clinical depression for many years, coming up with different kinds of psychotropic drugs and therapeutic treatments, but the disease never went away and suicide rates remain critically high.


Recently, the scientists and doctors came up with a drug that might become a breakthrough in treating depression, especially the treatment-resistant type. The US Food and Drugs Administration (FDA) approved a new medical development - a antidepressant in the form of a nasal spray, called Spravato (the brand name) or esketamine (the substance). Source: npr.org
According to Tiffany Farchione, M.D, a leading doctor at FDA’s Division of Psychiatry Products: "There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition.”
Chemically, the new antidepressant esketamine is quite close to ketamine, a drug used as a painkiller, for anesthesia and a popular party drug known for its strong dissociative effects. Spravato is claimed to have positive effects on patients diagnosed with clinical depression in a matter of couple of hours, while the alternative drugs can make a similar influence only in the course of a few weeks. Esketamine was found after the thorough research made on ketamine many years ago. Back then, the study showed that ketamine had a positive effect on people with major depressive disorder.  The newly-developed drug has already proved efficient on multiple patients that resisted all other types of treatment. Spravato will be manufactured by the company Johnson & Johnson, but it will not be publicly available.
Because of the risk of serious adverse outcomes resulting from sedation and dissociation caused by Spravato administration, and the potential for abuse and misuse of the drug, it is only available through a restricted distribution system, under a Risk Evaluation and Mitigation Strategy,” is mentioned in the press release.
Subscribe to The Coin Shark news in Facebook: https://www.facebook.com/coinshark/